Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 32003D0296

    2003/296/EC: Commission Decision of 28 April 2003 appointing members of the Committee for Orphan Medicinal Products (Text with EEA relevance)

    ELT L 106, 29.4.2003, p. 35–35 (ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)

    Legal status of the document No longer in force, Date of end of validity: 16/04/2006

    ELI: http://data.europa.eu/eli/dec/2003/296/oj

    Date of document:
    28/04/2003
    Date of effect:
    16/04/2003; Kohaldamine vt artikkel 2
    Date of effect:
    28/04/2003; jõustumine dokumendi kuupäev
    Date of end of validity:
    16/04/2006; ametiaja lõpp
    Author:
    Euroopa Komisjon
    Form:
    Otsus
    Additional information:
    EMP tähtsus
    Treaty:
    Euroopa Ühenduse asutamisleping
    Legal basis:
    Link
    Link
    Link
    Select all documents mentioning this document
    Link

    32003D0296

    2003/296/EC: Commission Decision of 28 April 2003 appointing members of the Committee for Orphan Medicinal Products (Text with EEA relevance)

    Official Journal L 106 , 29/04/2003 P. 0035 - 0035


    Commission Decision

    of 28 April 2003

    appointing members of the Committee for Orphan Medicinal Products

    (Text with EEA relevance)

    (2003/296/EC)

    THE COMMISSION OF THE EUROPEAN COMMUNITIES,

    Having regard to the Treaty establishing the European Community,

    Having regard to Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products(1), and in particular Article 4(3) thereof,

    Whereas:

    (1) The term of office of the members of the Committee for Orphan Medicinal Products, hereinafter "the Committee" set up in accordance with Article 4 of Regulation (EC) No 141/2000 expires on 15 April 2003. It is necessary, therefore, to appoint a new member and to renew the terms of office of certain existing members.

    (2) The European Agency for the Evaluation of Medicinal Products has recommended three persons for nomination.

    (3) The members of the Committee should be appointed for a period of three years starting on 16 April 2003,

    HAS DECIDED AS FOLLOWS:

    Article 1

    1. The following is hereby appointed member of the Committee for Orphan Medicinal Products, hereinafter referred to as "the Committee", to represent patients' organisations for a term of three years, from 16 April 2003:

    Birthe Holm.

    2. The following are hereby reappointed members of the Committee to represent patients' organisations for a term of three years, from 16 April 2003:

    Yann Le Cam

    Alastair Kent.

    Article 2

    On the recommendation of the European Agency for the Evaluation of Medicinal Products, the following are hereby reappointed members of the Committee for a term of three years, from 16 April 2003:

    Dr Eric Abadie

    Dr David Lyons

    Prof. Gianmartino Benzi.

    Done at Brussels, 28 April 2003.

    For the Commission

    Erkki Liikanen

    Member of the Commission

    (1) OJ L 18, 22.1.2000, p. 1.

    Top